[1] |
Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer[J]. Lancet, 2021, 397(10272):428-444.
|
[2] |
Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, Compton K, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019[J]. JAMA Oncol, 2022, 8(3):420-444.
|
[3] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1):7-33.
|
[4] |
Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma[J]. Liver Int, 2019, 39 Suppl 1: 98-107.
|
[5] |
Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma[J]. Gastroenterology, 2013, 145(6):1215-1229.
|
[6] |
Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent[J]. Br J Surg, 2018, 105(7):848-856.
|
[7] |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14):1273-1281.
|
[8] |
Boilève A, Hilmi M, Smolenschi C, et al. Immunotherapy in advanced biliary tract cancers[J]. Cancers, 2021, 13(7):1569.
|
[9] |
Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA classⅠantigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma[J]. Clin Cancer Res, 2016, 22(2):470-478.
|
[10] |
Ahn S, Lee Y, Kim JW, et al. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies[J]. Histopathology, 2019, 75(4):526-536.
|
[11] |
Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26):2509-2520.
|
[12] |
Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency[J]. Chin Clin Oncol, 2016, 5(5):62.
|
[13] |
Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6):888-894.
|
[14] |
Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(8):611-621.
|
[15] |
Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies[J]. Int J Cancer, 2020, 147(8):2190-2198.
|
[16] |
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8):773-779.
|
[17] |
Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(11):1480-1492.
|
[18] |
Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma[J]. Clin Cancer Res, 2021, 27(1):78-86.
|
[19] |
Sahai V, Griffith KA, Beg MS, et al. A multicenter randomized phaseⅡstudy of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first-line therapy for patients with advanced unresectable biliary tract cancer (BilT-01)[J]. J Clin Oncol, 2020, 38(15 suppl):4582-4582.
|
[20] |
Klein O, Kee D, Nagrial A, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial[J]. JAMA Oncol, 2020, 6(9):1405-1409.
|
[21] |
Ioka T, Ueno M, Oh DY, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC)[J]. J Clin Oncol, 2019, 37(4 suppl): 387.
|
[22] |
Zhang Q, Liu X, Wei S, et al. Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phaseⅡstudy[J]. Front Oncol, 2021(11): 751391.
|
[23] |
Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma[J]. Br J Cancer, 2008, 98(2):418-425.
|
[24] |
Tang D, Nagano H, Yamamoto H, et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance[J]. Oncol Rep, 2006, 15(3):525-532.
|
[25] |
Arkenau HT, Martin-Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label,phaseⅠtrial (JVDF)[J]. Oncologist, 2018, 23(12):1407-e136.
|
[26] |
Yoo C, Oh DY, Choi HJ, et al. phaseⅠstudy of bintrafuspalfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer[J]. J Immunother Cancer, 2020, 8(1):e000564.
|
[27] |
Aruga A, Takeshita N, Kotera Y, et al. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer[J]. Clin Cancer Res, 2013, 19(8):2224-2231.
|
[28] |
Aruga A, Takeshita N, Kotera Y, et al. phaseⅠclinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer[J]. J Transl Med, 2014(12):61.
|
[29] |
Shirahama T, Muroya D, Matsueda S, et al. A randomized phaseⅡ trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer[J]. Cancer Sci, 2017, 108(5):838-845.
|
[30] |
Goldstein D, Lemech C, Valle J. New molecular and immunotherapeutic approaches in biliary cancer[J]. ESMO Open, 2017, 2(Suppl 1):e000152.
|
[31] |
Yamamoto K, Ueno T, Kawaoka T, et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer[J]. Anticancer Res, 2005, 25(5):3575-3579.
|
[32] |
Feng K, Liu Y, Guo Y, et al. phaseⅠstudy of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers[J]. Protein Cell, 2018, 9(10): 838-847.
|
[33] |
Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer[J]. Science, 2014, 344(6184): 641-645.
|